SEC Filings
Repligen Brings In $458.6 Million Cash And Moves Exchanged Debt To 2031
The completed financing carries 0.25% annual interest, while approximately $143.2 million of the 2028 notes remains outstanding.
Repligen (RGEN) news from Bullished: SEC filings, earnings, insider trades and deals, explained in plain English with links to the source documents.
SEC Filings
The completed financing carries 0.25% annual interest, while approximately $143.2 million of the 2028 notes remains outstanding.
SEC Filings
The charge pushed a quarterly operating loss of $29.5 million; a $120.0 million stock buyback rides on the new notes.
Deals
The notes due 2031 convert at about $226.37 a share, and Repligen will use $120.0 million of the cash raised to buy back its own stock.
Earnings
The CEO said at least 25% reported growth is in reach next year, with formal guidance due toward the end of February.
Earnings
Capital equipment orders rose mid-teens, but buyers are slow to commit, so most of the revenue lands in 2027, the CEO said.
Earnings
Adjusted earnings rose to $0.53 a share in the third quarter, while standard accounting shows a $0.68 per-share loss.
SEC Filings
BioLife has ceased to exist as a separate legal entity and asked Nasdaq to delist its stock, an 8-K shows.